A novel circ_0099999/miR-330-5p/FSCN1 ceRNA crosstalk in pancreatic cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Ansari D, Tingstedt B, Andersson B, et al. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol. 2016;12(16):1929–1946.
   PubMed Web of Science ®Google Scholar
• Strobel O, Neoptolemos J, Jäger D, et al. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. 2019;16(1):11–26.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Kleeff J, Michl P, et al. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15(6):333–348.
   PubMed Web of Science ®Google Scholar
• Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333–338.
   PubMed Web of Science ®Google Scholar
• Patop IL, Wüst S, Kadener S. Past, present, and future of circRNAs. EMBO J. 2019;38(16):e100836.
   PubMed Web of Science ®Google Scholar
• Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505(7483):344–352.
   PubMed Web of Science ®Google Scholar
• Lu J, Xu X, Li Y, et al. CircRAB3B suppresses proliferation, motility, cell cycle progression and promotes the apoptosis of IL-22-induced keratinocytes depending on the regulation of miR-1228-3p/PTEN axis in psoriasis. Autoimmunity. 2021;7:1–10.
   Google Scholar
• Wang S, Feng X, Wang Y, et al. Dysregulation of tumour microenvironment driven by circ-TPGS2/miR-7/TRAF6/NF-κB axis facilitates breast cancer cell motility. Autoimmunity. 2021;26:1–10.
   Google Scholar
• Wang YZ, An Y, Li BQ, et al. Research progress on circularRNAs in pancreatic cancer: emerging but promising. Cancer Biol Ther. 2019;20(9):1163–1171.
   PubMed Web of Science ®Google Scholar
• Lin Z, Lu S, Xie X, et al. Noncoding RNAs in drug-resistant pancreatic cancer: a review. Biomed Pharmacother. 2020;131:110768.
   PubMed Web of Science ®Google Scholar
• Zhang T, Li M, Lu H, et al. Up-regulation of circEIF6 contributes to pancreatic cancer development through targeting miR-557/SLC7A11/PI3K/AKT signaling. Cancer Manag Res. 2021;13:247–258.
   PubMed Web of Science ®Google Scholar
• Zhu P, Ge N, Liu D, et al. Preliminary investigation of the function of hsa_circ_0006215 in pancreatic cancer. Oncol Lett. 2018;16:603–611.
   PubMed Web of Science ®Google Scholar
• Zhang X, Tan P, Zhuang Y, et al. Hsa_circRNA_001587 upregulates SLC4A4 expression to inhibit migration, invasion, and angiogenesis of pancreatic cancer cells via binding to microRNA-223. Am J Physiol Gastrointest Liver Physiol. 2020;319(6):G703–G717.
   PubMed Web of Science ®Google Scholar
• An Y, Cai H, Zhang Y, et al. circZMYM2 competed endogenously with miR-335-5p to regulate JMJD2C in pancreatic cancer. Cell Physiol Biochem. 2018;51(5):2224–2236.
   PubMedGoogle Scholar
• Jafarinejad-Farsangi S, Gharibdoost F, Farazmand A, et al. MicroRNA-21 and microRNA-29a modulate the expression of collagen in dermal fibroblasts of patients with systemic sclerosis. Autoimmunity. 2019;52(3):108–116.
   PubMed Web of Science ®Google Scholar
• Zan H, Tat C, Casali P. MicroRNAs in lupus. Autoimmunity. 2014;47(4):272–285.
   PubMed Web of Science ®Google Scholar
• Daoud AZ, Mulholland EJ, Cole G, et al. MicroRNAs in pancreatic cancer: biomarkers, prognostic, and therapeutic modulators. BMC Cancer. 2019;19(1):1130.
   PubMed Web of Science ®Google Scholar
• Abreu FB, Liu X, Tsongalis GJ. miRNA analysis in pancreatic cancer: the Dartmouth experience. Clin Chem Lab Med. 2017;55(5):755–762.
   PubMed Web of Science ®Google Scholar
• Tréhoux S, Lahdaoui F, Delpu Y, et al. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. Biochim Biophys Acta. 2015;1853(10 Pt A):2392–2403.
   PubMed Web of Science ®Google Scholar
• Chen S, Chen JZ, Zhang JQ, et al. Silencing of long noncoding RNA LINC00958 prevents tumor initiation of pancreatic cancer by acting as a sponge of microRNA-330-5p to down-regulate PAX8. Cancer Lett. 2019;446:49–61.
   PubMed Web of Science ®Google Scholar
• Eling N, Reuter L, Hazin J, et al. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience. 2015;2(5):517–532.
   PubMedGoogle Scholar
• Hatley ME, Patrick DM, Garcia MR, et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell. 2010;18(3):282–293.
   PubMed Web of Science ®Google Scholar
• Kristensen LS, Hansen TB, Venø MT, et al. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene. 2018;37(5):555–565.
   PubMed Web of Science ®Google Scholar
• Verduci L, Strano S, Yarden Y, et al. The circRNA-microRNA code: emerging implications for cancer diagnosis and treatment. Mol Oncol. 2019;13(4):669–680.
   PubMed Web of Science ®Google Scholar
• Akram M. Mini-review on glycolysis and cancer. J Cancer Educ. 2013;28(3):454–457.
   PubMed Web of Science ®Google Scholar
• Garcia SN, Guedes RC, Marques MM. Unlocking the potential of HK2 in cancer metabolism and therapeutics. Curr Med Chem. 2019;26(41):7285–7322.
   PubMed Web of Science ®Google Scholar
• Pathria G, Scott DA, Feng Y, et al. Targeting the Warburg effect via LDHA inhibition engages ATF4 signaling for cancer cell survival. EMBO J. 2018;37(20):e99735.
   PubMed Web of Science ®Google Scholar
• Zheng X, Chen L, Zhou Y, et al. A novel protein encoded by a circular RNA circPPP1R12A promotes tumor pathogenesis and metastasis of colon cancer via Hippo-YAP signaling. Mol Cancer. 2019;18(1):47.
   PubMed Web of Science ®Google Scholar
• Chen F, Feng Z, Zhu J, et al. Emerging roles of circRNA_NEK6 targeting miR-370-3p in the proliferation and invasion of thyroid cancer via wnt signaling pathway. Cancer Biol Ther. 2018;19(12):1139–1152.
   PubMed Web of Science ®Google Scholar
• Wang H, Liu L, Fang S. MicroRNA-330-5p inhibits osteosarcoma cell growth and invasion by targeting the proto-oncogene survivin. Mol Med Rep. 2019;20(3):2236–2244.
   PubMed Web of Science ®Google Scholar
• Feng L, Ma J, Ji H, et al. miR-330-5p suppresses glioblastoma cell proliferation and invasiveness through targeting ITGA5. Biosci Rep. 2017;37:BSR20170019.
   PubMed Web of Science ®Google Scholar
• Xiao S, Yang M, Yang H, et al. miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling. Oncogenesis. 2018;7(11):90.
   PubMedGoogle Scholar
• Cui L, Nai M, Zhang K, et al. lncRNA WT1-AS inhibits the aggressiveness of cervical cancer cell via regulating p53 expression via sponging miR-330-5p. Cancer Manag Res. 2019;11:651–667.
   PubMed Web of Science ®Google Scholar
• Xu S, Lei SL, Liu KJ, et al. circSFMBT1 promotes pancreatic cancer growth and metastasis via targeting miR-330-5p/PAK1 axis. Cancer Gene Ther. 2021;28(3–4):234–249.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xia L, Dong L, et al. CircHIPK3 promotes gemcitabine (GEM) resistance in pancreatic cancer cells by sponging miR-330-5p and targets RASSF1. Cancer Manag Res. 2020;12:921–929.
   PubMed Web of Science ®Google Scholar
• Mahdiannasser M, Haghpanah V, Damavandi E, et al. Investigation of promoter methylation of FSCN1 gene and FSCN1 protein expression in differentiated thyroid carcinomas. Mol Biol Rep. 2020;47(3):2161–2169.
   PubMed Web of Science ®Google Scholar
• Alajez NM. Significance of BMI1 and FSCN1 expression in colorectal cancer. Saudi J Gastroenterol. 2016;22(4):288–293.
   PubMed Web of Science ®Google Scholar
• Hanker LC, Karn T, Holtrich U, et al. Prognostic impact of fascin-1 (FSCN1) in epithelial ovarian cancer. Anticancer Res. 2013;33(2):371–377.
   PubMed Web of Science ®Google Scholar
• Liang J, Liu Z, Wei X, et al. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients. BMC Cancer. 2019;19(1):1165.
   PubMed Web of Science ®Google Scholar
• Chen Y, Tian T, Li ZY, et al. FSCN1 is an effective marker of poor prognosis and a potential therapeutic target in human tongue squamous cell carcinoma. Cell Death Dis. 2019;10(5):356.
   PubMedGoogle Scholar
• Tsai WC, Lin CK, Lee HS, et al. The correlation of cortactin and fascin-1 expression with clinicopathological parameters in pancreatic and ampulla of Vater adenocarcinoma. APMIS. 2013;121(3):171–181.
   PubMed Web of Science ®Google Scholar
• Misiura M, Zińczuk J, Zaręba K, et al. Actin-bundling proteins (actinin-4 and fascin-1) are involved in the development of pancreatic intraepithelial neoplasia (PanIN). Am J Med Sci. 2020;359(3):147–155.
   PubMed Web of Science ®Google Scholar
• Zhao X, Gao S, Ren H, et al. Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin. Cancer Res. 2014;74(9):2455–2464.
   PubMed Web of Science ®Google Scholar
• Qin Y, Dang X, Li W, et al. miR-133a functions as a tumor suppressor and directly targets FSCN1 in pancreatic cancer. Oncol Res. 2013;21(6):353–363.
   PubMed Web of Science ®Google Scholar